Sigyn Therapeutics (SIGY) Common Equity (2016 - 2025)

Sigyn Therapeutics has disclosed Common Equity across 10 years of filings, most recently posting -$5.9 million for Q3 2025.

• In Q3 2025, Common Equity fell 50.85% year-over-year to -$5.9 million; the TTM figure through Sep 2025 stood at -$5.9 million (down 50.85% YoY), while the FY2024 annual figure was -$4.5 million, down 30.63% from the prior year.
• Common Equity came in at -$5.9 million for Q3 2025 at Sigyn Therapeutics, down from -$5.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $977137.0 in Q2 2021 to a low of -$5.9 million in Q3 2025.
• Average Common Equity over 5 years is -$2.6 million, with a median of -$3.0 million recorded in 2023.
• Year-over-year, Common Equity soared 617.73% in 2021 and slumped 811.58% in 2022.
• Over 5 years, Common Equity stood at -$264584.0 in 2021, then slumped by 619.33% to -$1.9 million in 2022, then slumped by 79.3% to -$3.4 million in 2023, then slumped by 30.63% to -$4.5 million in 2024, then plunged by 32.74% to -$5.9 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were -$5.9 million in Q3 2025, -$5.4 million in Q2 2025, and -$4.9 million in Q1 2025.